C67 SUPPURATIVE LUNG DISEASES IN CHILDREN: Application Of Pharmacokinetics And Pharmacodynamics To Determine Dose Optimization Using Beta Lactams In Pediatric Cystic Fibrosis Population

C67 SUPPURATIVE LUNG DISEASES IN CHILDREN: Application Of Pharmacokinetics And Pharmacodynamics To Determine Dose Optimization Using Beta Lactams In Pediatric Cystic Fibrosis Population

Rationale: Acute and chronic bacterial infections cause acute pulmonary exacerbations (APE) with tremendous morbidity and mortality in patients with cystic fibrosis (CF). CF patients could benefit from therapeutic drug monitoring to improve beta lactam antibiotic exposure and clinical outcomes, espe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Hauptverfasser: Jensen, C, Fanous, H, Chaney, H R, Sami-Zakhari, I R, Perez, G F, Louie, S, Hahn, A
Format: Artikel
Sprache:eng
Schlagworte:
Antibiotics
Cystic fibrosis
Drug dosages
Pediatrics
Pharmacodynamics
Pharmacokinetics
Therapeutic drug monitoring
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title American journal of respiratory and critical care medicine
container_volume 195
creator Jensen, C
Fanous, H
Chaney, H R
Sami-Zakhari, I R
Perez, G F
Louie, S
Hahn, A
description Rationale: Acute and chronic bacterial infections cause acute pulmonary exacerbations (APE) with tremendous morbidity and mortality in patients with cystic fibrosis (CF). CF patients could benefit from therapeutic drug monitoring to improve beta lactam antibiotic exposure and clinical outcomes, especially when treating antibiotic resistant organisms.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1926716409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1926716409</sourcerecordid><originalsourceid>FETCH-proquest_journals_19267164093</originalsourceid><addsrcrecordid>eNqNjMtOg0AYhYnRxHp5hz9xTTIUCuIOgdpJCCUFjLtmhKlOhRmcf1i0b-bbiZe4dnVOvnM5sWbOwl3YXhiQ08mTwLU9L3w6ty4Q94Q481uHzKyP2A-grIui3kQVfUwhq_MHSGiZRmVaAs0hXtEs2aT5HUTD0ImGGaEkrHdQvDLds0a9CcmNaBAi2f7B9iBZ_wUrBQk3XPdTCxKFHNaDEb04_vzUKOQL3HPDIGONYT0ClVDwVjCjRQPxAadvWIpnrVAgFGoYu-_plXW2Yx3y61-9tG6WaRWv7EGr95Gj2e7VqOUUbZ1w7geO75HQ_V_rE3hpYxc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1926716409</pqid></control><display><type>article</type><title>C67 SUPPURATIVE LUNG DISEASES IN CHILDREN: Application Of Pharmacokinetics And Pharmacodynamics To Determine Dose Optimization Using Beta Lactams In Pediatric Cystic Fibrosis Population</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Ovid Autoload</source><source>American Thoracic Society (ATS) Journals Online</source><source>Alma/SFX Local Collection</source><creator>Jensen, C ; Fanous, H ; Chaney, H R ; Sami-Zakhari, I R ; Perez, G F ; Louie, S ; Hahn, A</creator><creatorcontrib>Jensen, C ; Fanous, H ; Chaney, H R ; Sami-Zakhari, I R ; Perez, G F ; Louie, S ; Hahn, A</creatorcontrib><description>Rationale: Acute and chronic bacterial infections cause acute pulmonary exacerbations (APE) with tremendous morbidity and mortality in patients with cystic fibrosis (CF). CF patients could benefit from therapeutic drug monitoring to improve beta lactam antibiotic exposure and clinical outcomes, especially when treating antibiotic resistant organisms.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><language>eng</language><publisher>New York: American Thoracic Society</publisher><subject>Antibiotics ; Cystic fibrosis ; Drug dosages ; Pediatrics ; Pharmacodynamics ; Pharmacokinetics ; Therapeutic drug monitoring</subject><ispartof>American journal of respiratory and critical care medicine, 2017-01, Vol.195</ispartof><rights>Copyright American Thoracic Society 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782</link.rule.ids></links><search><creatorcontrib>Jensen, C</creatorcontrib><creatorcontrib>Fanous, H</creatorcontrib><creatorcontrib>Chaney, H R</creatorcontrib><creatorcontrib>Sami-Zakhari, I R</creatorcontrib><creatorcontrib>Perez, G F</creatorcontrib><creatorcontrib>Louie, S</creatorcontrib><creatorcontrib>Hahn, A</creatorcontrib><title>C67 SUPPURATIVE LUNG DISEASES IN CHILDREN: Application Of Pharmacokinetics And Pharmacodynamics To Determine Dose Optimization Using Beta Lactams In Pediatric Cystic Fibrosis Population</title><title>American journal of respiratory and critical care medicine</title><description>Rationale: Acute and chronic bacterial infections cause acute pulmonary exacerbations (APE) with tremendous morbidity and mortality in patients with cystic fibrosis (CF). CF patients could benefit from therapeutic drug monitoring to improve beta lactam antibiotic exposure and clinical outcomes, especially when treating antibiotic resistant organisms.</description><subject>Antibiotics</subject><subject>Cystic fibrosis</subject><subject>Drug dosages</subject><subject>Pediatrics</subject><subject>Pharmacodynamics</subject><subject>Pharmacokinetics</subject><subject>Therapeutic drug monitoring</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNjMtOg0AYhYnRxHp5hz9xTTIUCuIOgdpJCCUFjLtmhKlOhRmcf1i0b-bbiZe4dnVOvnM5sWbOwl3YXhiQ08mTwLU9L3w6ty4Q94Q481uHzKyP2A-grIui3kQVfUwhq_MHSGiZRmVaAs0hXtEs2aT5HUTD0ImGGaEkrHdQvDLds0a9CcmNaBAi2f7B9iBZ_wUrBQk3XPdTCxKFHNaDEb04_vzUKOQL3HPDIGONYT0ClVDwVjCjRQPxAadvWIpnrVAgFGoYu-_plXW2Yx3y61-9tG6WaRWv7EGr95Gj2e7VqOUUbZ1w7geO75HQ_V_rE3hpYxc</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Jensen, C</creator><creator>Fanous, H</creator><creator>Chaney, H R</creator><creator>Sami-Zakhari, I R</creator><creator>Perez, G F</creator><creator>Louie, S</creator><creator>Hahn, A</creator><general>American Thoracic Society</general><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20170101</creationdate><title>C67 SUPPURATIVE LUNG DISEASES IN CHILDREN: Application Of Pharmacokinetics And Pharmacodynamics To Determine Dose Optimization Using Beta Lactams In Pediatric Cystic Fibrosis Population</title><author>Jensen, C ; Fanous, H ; Chaney, H R ; Sami-Zakhari, I R ; Perez, G F ; Louie, S ; Hahn, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_19267164093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antibiotics</topic><topic>Cystic fibrosis</topic><topic>Drug dosages</topic><topic>Pediatrics</topic><topic>Pharmacodynamics</topic><topic>Pharmacokinetics</topic><topic>Therapeutic drug monitoring</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jensen, C</creatorcontrib><creatorcontrib>Fanous, H</creatorcontrib><creatorcontrib>Chaney, H R</creatorcontrib><creatorcontrib>Sami-Zakhari, I R</creatorcontrib><creatorcontrib>Perez, G F</creatorcontrib><creatorcontrib>Louie, S</creatorcontrib><creatorcontrib>Hahn, A</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jensen, C</au><au>Fanous, H</au><au>Chaney, H R</au><au>Sami-Zakhari, I R</au><au>Perez, G F</au><au>Louie, S</au><au>Hahn, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>C67 SUPPURATIVE LUNG DISEASES IN CHILDREN: Application Of Pharmacokinetics And Pharmacodynamics To Determine Dose Optimization Using Beta Lactams In Pediatric Cystic Fibrosis Population</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><date>2017-01-01</date><risdate>2017</risdate><volume>195</volume><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>Rationale: Acute and chronic bacterial infections cause acute pulmonary exacerbations (APE) with tremendous morbidity and mortality in patients with cystic fibrosis (CF). CF patients could benefit from therapeutic drug monitoring to improve beta lactam antibiotic exposure and clinical outcomes, especially when treating antibiotic resistant organisms.</abstract><cop>New York</cop><pub>American Thoracic Society</pub></addata></record>
fulltext fulltext
identifier ISSN: 1073-449X
ispartof American journal of respiratory and critical care medicine, 2017-01, Vol.195
issn 1073-449X
1535-4970
language eng
recordid cdi_proquest_journals_1926716409
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Ovid Autoload; American Thoracic Society (ATS) Journals Online; Alma/SFX Local Collection
subjects Antibiotics
Cystic fibrosis
Drug dosages
Pediatrics
Pharmacodynamics
Pharmacokinetics
Therapeutic drug monitoring
title C67 SUPPURATIVE LUNG DISEASES IN CHILDREN: Application Of Pharmacokinetics And Pharmacodynamics To Determine Dose Optimization Using Beta Lactams In Pediatric Cystic Fibrosis Population
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T05%3A11%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=C67%20SUPPURATIVE%20LUNG%20DISEASES%20IN%20CHILDREN:%20Application%20Of%20Pharmacokinetics%20And%20Pharmacodynamics%20To%20Determine%20Dose%20Optimization%20Using%20Beta%20Lactams%20In%20Pediatric%20Cystic%20Fibrosis%20Population&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=Jensen,%20C&rft.date=2017-01-01&rft.volume=195&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/&rft_dat=%3Cproquest%3E1926716409%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1926716409&rft_id=info:pmid/&rfr_iscdi=true